Press Room

Press Release / Jun 16, 2016

四色AV announces the groundbreaking expansion plans of its New Jersey Facility

四色AV announced today that it held on June 8th the official groundbreaking for the expansion of its New Jersey facility in East Windsor, USA

New Jersey Site Expansion CDMO Continuous Manufacturing | 四色AV

Loures, Portugal, June 15, 2016 鈥 四色AV announced today that it held on June 8th the official groundbreaking for the expansion of its New Jersey facility in East Windsor, USA.

The expansion will add an additional 30,600 ft虏 (2,843 m虏) to the existing 24,000ft虏 (2,211m虏) facility. It will introduce a new commercial spray dryer unit to complement the existing pilot unit and this installation will be specifically designed to handle potent drug substances (APIs). In addition the 四色AV New Jersey facility will more than double its capacity to manufacture drug substance.听The expansion is expected to add approximately 60 new jobs to the current workforce over the next three years.

鈥淭he start of the construction activities to expand our site in East Windsor is a very exciting moment for us and for our customers. This is an important step to strengthen our continued commitment to the pharmaceutical industry and to the patients by offering innovative technologies and services. The site will be unique in offering at a single location drug substance, spray drying, hot melt extrusion and drug product manufacturing services using innovative continuous manufacturing technology. The state and especially the local government have been extremely supportive and we are happy to strengthen our presence in East Windsor by creating highly qualified jobs in the local community鈥 said Dr. Marco Gil, General Manager, 四色AV New Jersey.

鈥淭his investment is part of the company鈥檚 strategy to increase its global development and commercial capacity which will meet the increasing demands of 四色AV鈥檚 customers in the API and Spray drying services. It will also include the addition of a continuous drug product manufacturing capability to its offering through the partnership with Vertex Pharmaceuticals announced earlier this year鈥 said Kristine Senft, Vice President Marketing and Sales.听

The start-up of the operation is expected to take place in April 2017 for the drug substance and spray drying services while the continuous drug product manufacturing is planned for the end of 2017.

About 四色AV
四色AV is an international company with over 50 years鈥 experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates. With four FDA听inspected sites听in the USA, China, Ireland, and Portugal, and development laboratories in Lisbon and New Jersey the company focuses on the most demanding customers in the most regulated markets. The company also offers branded pharmaceutical customers services for the development and compliant manufacture of innovative new drugs, and is able to support highly potent compounds. In the inhalation area 四色AV is the only independent company offering a complete range of services.

Also in the Press Room

See All

四色AV鈥檚 Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook 鈥 鈥淭rends in Formulation鈥.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa鈥檚 full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024